Faculty
Oncology Division
Todd A. Fehniger, MD, PhD
Professor
Department of Medicine
Oncology Division
Stem Cell Biology
Bone Marrow Transplantation & Leukemia
Clinical Interests
- Lymphoma
- Leukemia
- Immunotherapy
- Hematopoietic cell transplantation
Research Interests
- Innate immunity
- Natural killer cell biology
- Micro RNAs
- Cytokines
- Natural killer cell based therapeutics
Contact
- 314-747-1385 (office)
- 314-747-1547 (lab)
- 314-362-9333 (fax)
- tfehnige@wustl.edu
- Division of Oncology
Campus Box 8007
Washington University
660 South Euclid Avenue
St. Louis, MO 63110 - Room 638 Southwest Tower (office)
- Room 634 Southwest Tower (lab)
- Fehniger Laboratory
Biosketch
| Education | |
|---|---|
| 1994 | BS in Biological Sciences with High Distinction, State University of New York (SUNY), Buffalo, NY |
| 2000 | PhD in Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, College of Medicine and Public Health, Columbus, OH |
| 2002 | MD, The Ohio State University, College of Medicine and Public Health, Columbus, OH |
| Post-graduate Training | |
| 2002-2004 | Intern and Resident, Internal Medicine, Physician Scientist Training Pathway, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO |
| 2004-2008 | Fellow, Hematology and Oncology, Washington University School of Medicine, St. Louis, MO |
| Academic Positions & Employment | |
| 2008-2014 | Assistant Professor, Department of Medicine, Washington University School of Medicine, St. Louis, MO |
| 2015-2020 | Associate Professor, Department of Medicine, Washington University School of Medicine, St. Louis, MO |
| 2020-present | Professor, Department of Medicine, Washington University School of Medicine, St. Louis, MO |
| University & Hospital Appointments & Committees | |
| 2008-present | Member, Siteman Cancer Center, Hematopoietic Development and Malignancy Program; Lymphoma Program Co-Leader |
| 2008-present | Member, Division of Biology and Biomedical Sciences, Immunology Program, Washington University |
| 2008-present | Member, Institute for Clinical and Translational Sciences (ICTS), Washington University |
| 2009-2011 | Data Safety Monitoring Committee for investigator initiated clinical trial 07-0916: “Phase I trial of intravenous Decitabine in combination with Arsenic trioxide and Ascorbic acid in patients with myelodysplastic syndromes” |
| 2009-2013 | Reviewer, Translational Oncology Group Seed Funding, Division of Oncology |
| 2009 | Reviewer, BJHF/ICTS Clinical and Translational Research Funding Program |
| 2010-2013 | Siteman Cancer Center Shared Resource Review Committee |
| 2014-2018 | Leukemia SPORE DRP Review Committee |
| 2014-2017 | Reviewer, BJHF/ICTS Clinical and Translational Research Funding Program |
| 2014-2019 | Member, Siteman Cancer Center Investment Program Study Section |
| 2014-present | Member, WUSM Center for Human Immunology and Immunotherapy Programs (CHIIPs) |
| 2017-present | K12 Training Grant Review Committee |
| 2017-2018 | KL2 Training Grant Review Committee |
| 2018-present | Scientific Co-Director, Center for Gene and Cellular Immunotherapy, Division of Oncology, Department of Medicine, Washington University School of Medicine |
| 2018-present | Medical and Scientific Director, Biological Therapy Core Facility, Siteman Cancer Center, Washington University School of Medicine |
| Board Certification | |
| 2006 | ABIM Certified, Internal Medicine |
| 2009 | ABIM Certified, Medical Oncology |
| National or International Awards | |
| 1996 | Howard Hughes Medical Institute (HHMI) Research Fellowship for Medical Students |
| 1999, 2001 | American Society of Hematology (ASH) Travel Award |
| 2000 | ASH Medical Student (Trainee) Award |
| 2000 | American Association of Immunologists (AAI)-Huang Foundation Trainee Achievement Award |
| 2007 | American Society of Clinical Oncology (ASCO) Young Investigator Award |
| 2007 | Future Leader in Hematology Award (Celgene) |
| 2008 | ASCO Merit Award |
| 2008 | HHMI Physician Scientist Early Career Award |
| 2008 | Edward Mallinckrodt, Jr. Foundation Award |
| 2009 | ASH Scholar Award (Basic Science, Junior Faculty) |
| 2012 | V Scholar Award, V Foundation for Cancer Research |
| 2013 | ASH Bridge Grant Program Award (declined when R01 funded) |
| 2013 | Follicular Lymphoma Pathway Award, Lymphoma Research Foundation |
| 2014 | Gabrielle's Angel Foundation Medical Award |
| 2014 | AAI Junior Faculty Travel Award |
| 2016 | Elected Member, American Society for Clinical Investigation (ASCI) |
| 2017 | Children’s Discovery Institute, Interdisciplinary Award |
| 2017 | V Scholar Translational Research Award, V Foundation for Cancer Research |
| 2018 | Siteman Cancer Center "Rock Doc" Award |
| 2018 | Siteman Cancer Center Lymphoma Team Science Award |
| Editorial Responsibilities | |
| 2015-present | Review Editor, Frontiers in Molecular Innate Immunity |
| 2015 | Review Editor, Frontier in Immunology, NK cell biology |
| 2015-2018 | Editorial Board, Blood |
| 2016-2018 | Editorial Board, European Journal of Immunology |
| 2018-2023 | Deputy Editor, The Journal of Immunology |
| 2018 | Editor, Wintrobe’s Clinical Hematology, Edition 14 (Greer, Arber, Rodgers, Means, Appelbaum, Dispenzieri, Glader, List, Fehniger, editors). Wolters Kluwer, 2018 |
| Professional Societies & Organizations | |
| 2004-present | American Society of Hematology 2018-2023: ASH Scientific Committee on Immunology and Host Defense |
| 2004-present | American Society for Transplantation and Cellular Therapy |
| 2008-present | Society for Natural Immunity 2018-2021: President-Elect 2021-2024: President |
| 2008-present | Alliance Cooperative Group Lymphoma Committee, Member Lymphoma Translational Sciences, Vice Chair |
| 2010-present | American Association of Immunologists |
| 2010-present | American Association for Cancer Research 2013: AACR Annual Meeting Education Committee, Member |
| 2014-present | Site Co-PI, Clinical Immunotherapy Trials Network (CITN) |
